https://www.patientcareonline.com/view/tirzepatide-reduces-time-to-hba1c-targets-by-up-to-3-months-vs-semaglutide-insulin-degludec
0
0
9/15/22 at 6:12pm
Organization
Patientcareonline.com
Author
Grace Halsey
46 words
0
Comments
Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.
You are the first to view
Create an account
or login to join the discussion